Escucha el podcast OncLive® On Air

S13 Ep1: Cancer Vaccines Shake Up Disease Management and Prevention Strategies: With Shubham Pant, MD, MBBS; and Professor Timothy Elliott	OncLive® On Air	24:09
S12 Ep50: Optimizing Today and Looking to Tomorrow in Metastatic CRPC - Homing in on EZH2	OncLive® On Air	43:33
S12 Ep49: MEK Inhibitors Expand the NF1-Associated PN Treatment Paradigm: With Christopher L. Moertel, MD	OncLive® On Air	12:54
S12 Ep48: Innovations in HR+/HER2– Metastatic Breast Cancer: Advancing Care Through PROTAC ER Degradation	OncLive® On Air	77:00
S12 Ep47: Early-Phase RAS Inhibitor Research Sparks Interest in NSCLC: With Kathryn C. Arbour, MD	OncLive® On Air	09:43
S12 Ep46: Managing Side Effects and Fertility for Premenopausal Patients with Advanced HR+ Breast Cancer	OncLive® On Air	64:27
S12 Ep45: RP1 Plus Nivolumab Delivers Durable Responses in PD-1–Exposed Melanoma: With Anna C. Pavlick, BSN, MSc, DO, MBA	OncLive® On Air	10:56
S12 Ep44: Real-World Data Support Nadofaragene Firadenovec Use in BCG-Unresponsive NMIBC: With Jacob Moyer, BS; and Mark D. Tyson, II, MD, MPH	OncLive® On Air	12:33
S12 Ep43: Disease Features and Treatment Intolerance Inform Pirtobrutinib Use in Pretreated CLL: With Nicole Lamanna, MD	OncLive® On Air	19:32
S12 Ep42: Radioligand Therapy Advances Represent the Future of mCRPC Treatment: With Daniel P. Petrylak, MD	OncLive® On Air	07:28
S12 Ep41: Oncodetect MRD Detection Aids Treatment Decision-Making in CRC and Other Solid Tumors: With Eric Christenson, MD	OncLive® On Air	13:53
S12 Ep40: Motivation and Consistency Are Key to Building a Successful Oncology Educational Platform: With Chandler Park, MD; and Paul Hanona, MD	OncLive® On Air	09:12
S12 Ep39: Social Media Unlocks New Avenues for Expanding Access to Oncology Education: With Chandler Park, MD; and Paul Hanona, MD	OncLive® On Air	12:25
S12 Ep38: Incorporating Recent Updates in the Treatment of Metastatic ALK-Positive NSCLC	OncLive® On Air	44:04
S12 Ep37: Bladder-Sparing Strategies and ctDNA-Guided Strategies Take Center Stage in MIBC: With Chandler Park, MD; and Vadim Koshkin, MD	OncLive® On Air	05:28
S12 Ep36: Peer Support, Adaptability, and Self-Confidence Are Hallmarks of Successful Oncology Careers: With Liliana Bustamante, MD; and Jessica Stine, MD	OncLive® On Air	23:28
S12 Ep35: Innovative Research Raises Questions About the Role of ADCs in Bladder Cancer: With Chandler Park, MD; and Vadim Koshkin, MD	OncLive® On Air	13:06
S12 Ep34: AR Pathway Inhibition Refines Prostate Cancer Treatment Strategies: With Neal Shore, MD, FACS	OncLive® On Air	08:16
S12 Ep33: Comprehensive First-Line Bladder Cancer Treatment Begins With Careful Patient Selection: With Chandler Park, MD	OncLive® On Air	18:19
S12 Ep32: ADC-Based Combinations Gain Momentum in Bladder Cancer Management: With Chandler Park, MD; and Vadim Koshkin, MD	OncLive® On Air	10:30
S12 Ep31: Oncology Experts Discuss the Long-Term Effects of the COVID-19 Pandemic: With Ramez N. Eskander, MD; Rachel N. Grisham, MD; Benjamin Herzberg, MD; Kelly McCann, MD, PhD; and Gregory Roloff,	OncLive® On Air	13:54
S12 Ep30: Study Reveals Subgroups of Patients With RCC Who May Have Durable Responses to Immunotherapy: With David A. Braun, MD, PhD	OncLive® On Air	15:16
S12 Ep29: Strong Mentorship Opportunities Support the Next Generations of Women in Lymphoma: With Chandler Park, MD; and Ann S. LaCasce, MD, MMSc	OncLive® On Air	20:48
S12 Ep28: Ivonescimab Improves PFS vs Pembrolizumab in Advanced PD-L1+ NSCLC: With Xiuning Le, MD, PhD	OncLive® On Air	11:22
S12 Ep28: Ponatinib Monotherapy Maintains MRD Negativity Following TKI/Chemotherapy Treatment in Ph+ ALL: With Ibrahim T. Aldoss, MD; and Elias Jabbour, MD	OncLive® On Air	09:57
S12 Ep27: Venetoclax Plus Pegcrisantaspase Induces Remissions in R/R AML: With Ashkan Emadi, MD, PhD	OncLive® On Air	19:58
S12 Ep26: FDA Approval Insights: Tislelizumab Plus Chemo in Unresectable Metastatic ESCC: With Nataliya Uboha, MD, PhD	OncLive® On Air	09:30
S12 Ep25: Perioperative Durvalumab Improves Survival in MIBC: Navigating the NIAGARA Trial Findings With: Chandler Park, MD; and Petros Grivas, MD, PhD	OncLive® On Air	23:04
S12 Ep24: Expert Interpretations of the Latest Data in CLL Management – Understanding the Impact of Optimal Treatment Selection on Patient Outcomes	OncLive® On Air	54:09
S12 Ep23: Inavolisib Expands the PIK3CA-Mutated Metastatic HR+ Breast Cancer Treatment Paradigm: With Virginia Kaklamani, MD, DSc	OncLive® On Air	05:27
S12 Ep22: FDA Approval Insights: Vimseltinib for Symptomatic TGCT: With William D. Tap, MD	OncLive® On Air	07:48
S12 Ep21: Clinical Showcase™: Selecting the Best Next Steps for a Patient with Epithelioid Sarcoma	OncLive® On Air	30:09
S12 Ep20: FDA Approval Insights: Sotorasib Plus Panitumumab for KRAS G12C–Mutated mCRC: With Marwan Fakih, MD	OncLive® On Air	07:39
S12 Ep19: FDA Approval Insights: T-DXd in HER2-Low/-Ultralow Metastatic Breast Cancer: With Aditya Bardia, MD, MPH, FASCO	OncLive® On Air	07:20
S12 Ep18: Neoadjuvant MVAC/Pembrolizumab Generates Unprecedented pCR Rates in Non-Urothelial MIBC: With Chandler Park, MD; Petros Grivas, MD, PhD; and Ruben Raychaudhuri, MD	OncLive® On Air	20:33
S12 Ep17: Triplet Chemo Trial Raises Importance of Accurately Defined Subgroups in Biliary Tract Cancer Research: With Rachna Shroff, MD, MS, FASCO	OncLive® On Air	11:49
S12 Ep16: DA Approval Insights: Mirdametinib for NF1-Associated Plexiform Neurofibromas: With Christopher L. Moertel, MD	OncLive® On Air	11:18
S12 Ep15: Inavolisib Has a Favorable Risk-Benefit Profile for PIK3CA-Mutant, HR+ Metastatic Breast Cancer: With Komal Jhaveri, MD, FACP	OncLive® On Air	14:58
S12 Ep14: FDA Approval Insights: Dato-DXd for HR+/HER2-Negative Metastatic Breast Cancer: With Aditya Bardia, MD, MPH, FASCO	OncLive® On Air	06:33
S12 Ep13: Ponatinib-Based Regimens Strengthen the Ph+ ALL Treatment Paradigm: With Mark B. Geyer, MD, and Elias Jabbour, MD	OncLive® On Air	30:35

S13 Ep1: Cancer Vaccines Shake Up Disease Management and Prevention Strategies: With Shubham Pant, MD, MBBS; and Professor Timothy Elliott

OncLive® On Air

24:09

S12 Ep50: Optimizing Today and Looking to Tomorrow in Metastatic CRPC - Homing in on EZH2

OncLive® On Air

43:33

S12 Ep49: MEK Inhibitors Expand the NF1-Associated PN Treatment Paradigm: With Christopher L. Moertel, MD

OncLive® On Air

12:54

S12 Ep48: Innovations in HR+/HER2– Metastatic Breast Cancer: Advancing Care Through PROTAC ER Degradation

OncLive® On Air

77:00